Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 6, 2016, Pages 1641-1650

  Hoda, Muddasarul ^a   Pajaniradje, Sankar ^a   Shakya, Garima ^a   Mohankumar, Kumaravel ^a   Rajagopalan, Rukkumani ^a,b  

^a PONDICHERRY UNIVERSITY   (India)

^b UNIVERSITY OF MADRAS   (India)

Author keywords

Apoptosis; Biodegradable nanoparticles; Cancer; Disulfiram; PLGA

Indexed keywords

CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DOSAGE; DRUG PRODUCTS; TARGETED DRUG DELIVERY;

APOPTOTIC PATHWAYS; BIODEGRADABLE NANOPARTICLE; CANCER; DISULFIRAM; HEPATOCELLULAR CARCINOMA; PLGA; SUSTAINED DRUG RELEASE; TRIGGERING ACTIVATION;

NANOPARTICLES;

DISULFIRAM; POLYGLACTIN; POLYSORBATE 80; ALDEHYDE DEHYDROGENASE INHIBITOR; NANOPARTICLE; POLYSORBATE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; APOPTOSIS TRIGGERING POTENTIAL; ARTICLE; CARCINOMA CELL LINE; CELL AND NUCLEAR STAINING; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; COMET ASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; STAINING; SUSTAINED DRUG RELEASE; WESTERN BLOTTING; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; LIVER NEOPLASMS; TUMOR CELL LINE;

ACETALDEHYDE DEHYDROGENASE INHIBITORS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISULFIRAM; HUMANS; LIVER NEOPLASMS; NANOPARTICLES; POLYSORBATES;

EID: 84965032298     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.02.013     Document Type: Article

References (26)

1. Yuen M.F., Hou J.L., Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009, 24:346-353.
2. Chen D., Cui Q.C., Yang H., Dou Q.P. Disulfiram, a clinically used antialcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006, 66:10425-10433.
3. Brar S.S., Grigg C., Wilson K.S., Holder W.D., Dreau D., Austin C., et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther 2004, 3:1049-1060.
4. Daniel K.G., Chen D., Orlu S., Cui Q.C., Miller F.R., Dou Q.P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 2005, 7:R897-R908.
5. Shityakov S., Salvador E., Pastorin G., Forster C. Blood-brain barrier transports studies, aggregation, and molecular dynamics simulation of multiwalled carbon nanotube functionalized with fluorescein isothiocyanate. Int J Nanomedicine 2015, 10:1703-1713.
6. De jong W.H., Borm P.J.A. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine 2008, 3(2):133-149.
7. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol 2011, 9:55-66.
8. Hoda M., Sufi S.A., Shakya G., Kumarvel M.K., Rajagopalan R. Influence of stabilizers on the production of disulfiram-loaded poly (lactic-co-glycolic acid) nanoparticles and their anticancer potential. Ther Deliv 2015, 6(1):17-25.
9. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 1989, 55(1):R1-R4.
10. Olive P.L., Banath J.P., Durand R.E. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "Comet assay". Radiat Res 1990, 122:86-94.
11. Hengartner M.O. Biochemistry of apoptosis. Nature 2000, 407:770-776.
12. Sauna Z.E., Shukla S., Ambudkar S.V. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol Biosyst 2005, 1:127-134.
13. Bosch F.X., Ribes J., Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271-285.
14. Chiba T., Suzuki E., Yuki K., Zen Y., Oshima M., Miyagi S., et al. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners. PLoS One 2014, 9(1):e84807-e84817.
15. Knowles B.B., Howe C.C., Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980, 209:497-499.
16. Renvoize C., Biola A., Pallardy M., Breard J. Apoptosis: Identification of dying cells. Cell Biol Toxicol 1998, 14(2):111-120.
17. Cohen G.M., Sun X., Snowden R.T., Dinsdale D., Skilleter D.N. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem J 1992, 286:331-334.
18. Gyori B.M., Venkatachalam G., Thiagarajan P.S., Hsu D., Clement M.V. OpenComet: An automated tool for comet assay image analysis. Redox Biol 2014, 2:457-465.
19. Kumaravel T.S., Jha A.N. Reliable comet assay measurements for detecting DNA damage induced by ionising radiation and chemicals. Mutat Res 2006, 605:7-16.
20. MacLachlan T.K., Sang N., Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: Implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995, 5:127-156.
21. Pucci B., Kasten M., Giordano A. Cell cycle and apoptosis. Neoplasia 2000, 2(4):291-299.
22. Poulsen H.E., Loft S., Andersen J.R., Andersen M. Disulfiram therapy - adverse drug-reactions and interactions. Acta Psychiatr Scand 1992, 86:59-65.
23. Walczak H., Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2 L) apoptosis systems. Exp Cell Res 2000, 256(1):58-66.
24. Green D.R., Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004, 305(5684):626-629.
25. Cain K., Bratton S.B., Langlais C., Walker G., Brown D.G., Sun X.M. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. J Biol Chem 2000, 275:6067-6070.
26. Bibby D.C., Talmadge J.E., Dalal M.K., Kurz S.G., Chytil K.M., Barry S.E., et al. Pharmacokinetics and biodistribution of RG D-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharm 2005, 293:281-290.